

**Supplemental Table S3.** Checking Inconsistency between Direct and Indirect Estimates for Microalbuminuria, Macroalbuminuria, and Worsening Nephropathy

Comparison	k	prop	nma	direct	indirect	RoR	z	P value
Microalbuminuria								
DPP-4 inhibitors vs. placebo	2	0.96	0.85	0.85	0.80	1.06	0.21	0.83
SGLT2 inhibitors vs. placebo	4	0.98	0.65	0.65	0.69	0.94	-0.21	0.83
SGLT2 inhibitors vs. DPP-4 inhibitors	2	0.06	0.77	0.81	0.76	1.06	0.21	0.83
Macroalbuminuria								
DPP-4 inhibitors vs. placebo	2	0.99	0.85	0.85	0.86	0.99	-0.01	0.99
SGLT2 inhibitors vs. placebo	4	0.99	0.52	0.52	0.51	1.01	0.01	0.99
SGLT2 inhibitors vs. DPP-4 inhibitors	2	0.01	0.61	0.60	0.61	0.99	-0.01	0.99
Worsening nephropathy								
DPP-4 inhibitors vs. placebo	2	0.99	0.83	0.83	0.75	1.11	0.40	0.69
SGLT2 inhibitors vs. placebo	4	0.98	0.57	0.57	0.64	0.90	-0.40	0.69
SGLT2 inhibitors vs. DPP-4 inhibitors	2	0.04	0.69	0.76	0.69	1.11	0.40	0.69

k, number of studies providing direct evidence; prop, direct evidence proportion; nma, estimated treatment effect (odds ratio [OR]) in network meta-analysis; direct, estimated treatment effect (OR) derived from direct evidence; indirect, estimated treatment effect (OR) derived from indirect evidence; RoR, ratio of ratios (direct vs. indirect); z and P, values of tests for disagreement (direct vs. indirect); DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose cotransporter 2.